Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology, Surgical | 2 | 2018 | 151 | 0.670 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2019 | 1094 | 0.470 |
Why?
|
| Laboratories | 1 | 2018 | 461 | 0.460 |
Why?
|
| Endothelial Growth Factors | 7 | 1999 | 674 | 0.440 |
Why?
|
| Lymphokines | 7 | 1999 | 929 | 0.420 |
Why?
|
| Breast Neoplasms | 19 | 2019 | 21065 | 0.420 |
Why?
|
| Neovascularization, Pathologic | 8 | 2002 | 2641 | 0.410 |
Why?
|
| Carcinoma in Situ | 6 | 2015 | 796 | 0.400 |
Why?
|
| Receptors, Growth Factor | 5 | 1999 | 326 | 0.320 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2283 | 0.290 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 204 | 0.240 |
Why?
|
| Pathology, Clinical | 2 | 2019 | 375 | 0.240 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 1999 | 1614 | 0.200 |
Why?
|
| Breast | 5 | 2018 | 1980 | 0.190 |
Why?
|
| Lymph Nodes | 2 | 2002 | 3491 | 0.170 |
Why?
|
| Personnel Turnover | 1 | 2019 | 86 | 0.160 |
Why?
|
| Gynecomastia | 1 | 2019 | 87 | 0.150 |
Why?
|
| Microtomy | 1 | 1997 | 44 | 0.150 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 978 | 0.140 |
Why?
|
| Fluorouracil | 1 | 2002 | 1630 | 0.140 |
Why?
|
| Nipples | 1 | 2018 | 221 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2220 | 0.130 |
Why?
|
| Receptors, Mitogen | 1 | 1995 | 61 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factors | 7 | 1999 | 749 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2002 | 2207 | 0.120 |
Why?
|
| Professional Practice | 1 | 2017 | 313 | 0.120 |
Why?
|
| Carcinoma, Lobular | 3 | 2015 | 490 | 0.120 |
Why?
|
| Coloring Agents | 1 | 1997 | 561 | 0.120 |
Why?
|
| Linoleoyl-CoA Desaturase | 1 | 2013 | 4 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 1 | 1996 | 276 | 0.110 |
Why?
|
| Carbon | 1 | 1997 | 669 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2018 | 708 | 0.110 |
Why?
|
| Hyperplasia | 4 | 2019 | 1158 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 341 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 1008 | 0.100 |
Why?
|
| Carcinoma | 3 | 2018 | 2334 | 0.100 |
Why?
|
| Mammaplasty | 2 | 2019 | 1239 | 0.100 |
Why?
|
| Data Mining | 1 | 2016 | 553 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 1995 | 585 | 0.100 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 434 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 249 | 0.090 |
Why?
|
| Benchmarking | 1 | 2017 | 1043 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
| Medical Errors | 1 | 2016 | 1255 | 0.080 |
Why?
|
| In Situ Hybridization | 6 | 1999 | 1900 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 1067 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 1999 | 666 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 1996 | 1361 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 2178 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 1999 | 3483 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2002 | 11064 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1995 | 2018 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2019 | 1897 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 9274 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2002 | 3531 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2017 | 4786 | 0.050 |
Why?
|
| Female | 19 | 2019 | 391011 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11708 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 1999 | 12762 | 0.040 |
Why?
|
| Jordan | 1 | 2019 | 73 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4763 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 2019 | 209 | 0.040 |
Why?
|
| Humans | 25 | 2019 | 760261 | 0.040 |
Why?
|
| Cell Division | 2 | 1997 | 4462 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2002 | 673 | 0.040 |
Why?
|
| Axilla | 1 | 2000 | 618 | 0.040 |
Why?
|
| American Medical Association | 1 | 2017 | 60 | 0.040 |
Why?
|
| Age Factors | 3 | 2018 | 18415 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 221 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 1999 | 749 | 0.030 |
Why?
|
| Quality Control | 1 | 2019 | 827 | 0.030 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1996 | 57 | 0.030 |
Why?
|
| Observer Variation | 1 | 2002 | 2596 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 321 | 0.030 |
Why?
|
| Brazil | 1 | 2019 | 1214 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2000 | 2945 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1997 | 514 | 0.030 |
Why?
|
| Endometrium | 1 | 1996 | 403 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2018 | 698 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 151 | 0.030 |
Why?
|
| Adult | 9 | 2019 | 219847 | 0.030 |
Why?
|
| Prognosis | 4 | 2018 | 29636 | 0.030 |
Why?
|
| Aged | 7 | 2019 | 168995 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 1997 | 593 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 1999 | 938 | 0.020 |
Why?
|
| Middle Aged | 8 | 2019 | 220175 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 58947 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3618 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 11141 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1997 | 4024 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
| Mastectomy | 1 | 2019 | 1834 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 4891 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 6830 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2019 | 64947 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 1999 | 4437 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 987 | 0.020 |
Why?
|
| Microcirculation | 1 | 1994 | 1279 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2019 | 80301 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 20048 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2508 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2012 | 963 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2000 | 10185 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 39254 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9629 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6545 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 12156 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 24086 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 2192 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 8805 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2202 | 0.020 |
Why?
|
| Internet | 1 | 2017 | 3074 | 0.020 |
Why?
|
| Mammography | 1 | 2015 | 2452 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 1994 | 2544 | 0.010 |
Why?
|
| Stromal Cells | 2 | 1999 | 1327 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15687 | 0.010 |
Why?
|
| Gene Expression | 1 | 1994 | 7592 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8018 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 21378 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3215 | 0.010 |
Why?
|
| Young Adult | 2 | 2019 | 58673 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 87747 | 0.010 |
Why?
|
| United States | 2 | 2019 | 72363 | 0.010 |
Why?
|
| Risk Factors | 2 | 2018 | 74269 | 0.010 |
Why?
|
| Versicans | 1 | 1999 | 40 | 0.010 |
Why?
|
| Decorin | 1 | 1999 | 38 | 0.010 |
Why?
|
| Fibrocystic Breast Disease | 1 | 1999 | 103 | 0.010 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 1999 | 141 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1999 | 153 | 0.010 |
Why?
|
| Thrombospondin 1 | 1 | 1999 | 257 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 13629 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1999 | 802 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1999 | 591 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 1999 | 558 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41317 | 0.010 |
Why?
|
| Fibronectins | 1 | 1999 | 721 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1999 | 517 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 829 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1697 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2018 | 54263 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1997 | 314 | 0.010 |
Why?
|
| Collagen | 1 | 1999 | 2635 | 0.010 |
Why?
|
| Family Health | 1 | 1995 | 1258 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1995 | 965 | 0.010 |
Why?
|
| Neoplasms | 1 | 1998 | 22066 | 0.010 |
Why?
|
| Biopsy | 1 | 1999 | 6775 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1999 | 3665 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 3613 | 0.000 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 4494 | 0.000 |
Why?
|
| Male | 1 | 2019 | 359413 | 0.000 |
Why?
|
| Disease Progression | 1 | 1995 | 13505 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1997 | 26168 | 0.000 |
Why?
|
| Animals | 1 | 1998 | 167940 | 0.000 |
Why?
|
Concepts
(153)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_